TABLE 1.
Baseline characteristics of study participants
| Characteristic | Overall | Participants with prior exposure to RAL | Participants unexposed to RAL |
|---|---|---|---|
| Total, n (%) | 53 (100.0) | 8 (15.1) | 45 (84.9) |
| Gender distribution, n (%) | |||
| Female | 29 (54.72) | 3 (37.5) | 26 (57.78) |
| Male | 24 (45.28) | 5 (62.5) | 19 (42.22) |
| Median age (interquartile range), yrs | 51 (40–55) | 51 (48–53) | 48 (40–58) |
| Residence, n (%) | |||
| Yaoundé | 31 (58.49) | 6 (75) | 25 (55.56) |
| Douala | 22 (41.51) | 2 (25) | 20 (44.44) |
| Median viremia before third-line initiation (interquartile range),HIV-1 RNA copies/mL | 3795 (220–169,322) | 13929 (2,724–15,916) | 2724 (199–101,030) |
| Median CD4 count before third-line initiation (interquartile range),cells/mm3 | 157 (84–285) | 195 (149 – 804) | 148 (75 – 226) |
| Median ART-duration (interquartile range), mo | 192 (162 – 222) | 192 (162 – 202) | 184 (162 – 222) |